antivir
agent
aid
hiv
tryptophan
previous
report
new
class
dendrim
tryptophan
trp
residu
surfac
show
dual
antivir
activ
hiv
enteroviru
prototyp
compound
famili
deriv
pentaerythritol
peripher
trp
group
trival
spacer
arm
novel
seri
dendrim
dival
tetraval
branch
arm
instead
trival
one
present
prototyp
synthes
activ
hiv
panel
differ
virus
pathogen
determin
converg
diverg
approach
use
synthesi
compound
find
demonstr
compound
tetraval
branch
arm
show
antihiv
activ
prototyp
low
micromolar
even
gain
signific
antivir
activ
new
pathogen
human
corona
viru
respiratori
syncyti
viru
first
member
trp
dendrim
famili
show
activ
virus
prototyp
compound
also
show
lownanomolar
activ
repres
clinic
isol
experiment
work
carri
determin
mode
action
potent
iia
contain
tetraval
branch
arm
demonstr
interact
viral
envelop
hiv
thu
may
prevent
viru
attach
host
cell
result
support
interest
new
seri
trp
dendrim
qualifi
use
prototyp
develop
novel
inhibitor
viral
entri
broad
antivir
spectrum
human
immunodefici
viru
hiv
etiolog
agent
acquir
immunodefici
syndrom
aid
devast
infecti
diseas
continu
major
global
public
health
problem
unaid
data
use
antiretrovir
therapi
art
improv
life
expect
transform
infect
manag
chronic
diseas
art
broder
mehel
volberd
zhan
despit
longterm
side
effect
latent
viral
infect
within
reservoir
develop
drug
resist
weaken
efficaci
clinic
avail
drug
drug
resist
data
base
margoli
roja
highlight
fact
new
inhibitor
antivir
treatment
strategi
constantli
need
badia
gulick
kumari
tintori
sens
initi
step
hiv
replic
cycl
entri
andor
fusion
host
cell
attract
target
kang
klase
lu
micewicz
wens
current
two
fdaapprov
entri
inhibitor
fuzeon
ding
fletcher
target
envelop
glycoprotein
maraviroc
woollard
target
host
cell
receptor
howev
despit
fact
envelop
glycoprotein
critic
hiv
entri
still
approv
drug
direct
toward
target
fostemsavir
phase
iii
clinic
trial
cahn
gulick
meanwel
vitoria
advanc
drug
class
previous
report
dendrim
deriv
peripher
tryptophan
trp
residu
trival
aliphat
branch
arm
exemplifi
dendrim
fig
inhibit
earli
step
replic
cycl
hiv
interact
glycoprotein
hiv
envelop
riverobuceta
due
current
interest
hiv
entri
inhibitor
associ
bind
interestingli
dendrim
also
prove
potent
specif
select
inhibitor
replic
unrel
enteroviru
riverobuceta
one
major
etiolog
agent
hand
foot
mouth
diseas
hfmd
occasion
associ
sever
neurolog
complic
young
children
baggen
mcminn
nadel
solomon
far
antivir
approv
treatprev
hfmd
infect
dendrim
inhibit
laboratori
strain
brcr
strain
also
larg
panel
clinic
isol
belong
genogroup
lownanomolarhighpicomolar
rang
riverobuceta
recent
demonstr
target
residu
structur
protein
particularli
region
form
vertex
viral
capsid
turn
block
bind
viru
host
cell
sun
respect
sar
studi
modif
made
central
core
peripheri
prototyp
rivero
buceta
buceta
modif
led
conclus
multival
present
trp
respect
indol
side
chain
free
cooh
requir
antivir
activ
hiv
compound
trival
spacer
arm
use
link
peripher
amino
acid
central
core
obtain
sar
inform
new
trp
dendrim
lower
higher
branch
degre
prepar
fig
lower
branch
degre
achiev
dival
branch
arm
fig
compound
iad
use
decreas
peripher
congest
highest
branch
degre
achiev
tetraval
branch
arm
fig
compound
iiad
maxim
multival
effect
central
scaffold
differ
architectur
flexibl
four
fig
compound
ia
iia
three
fig
compound
ibd
iibd
carboxyl
acid
attach
point
use
dendrim
iad
iiad
first
evalu
inhibitori
effect
replic
cell
cultur
tabl
summar
result
evalu
antivir
data
prototyp
includ
refer
well
dextran
neg
charg
hiv
adsorpt
inhibitor
baba
pradimycin
prma
carbohydratebind
entri
inhibitor
balzarini
synthes
compound
show
micromolar
activ
replic
dendrim
iiad
ec
ia
ec
peripher
trp
residu
respect
consider
activ
ibd
ec
peripher
trp
group
addit
iiad
well
ia
ibd
show
micromolar
activ
differ
activ
suggest
minimum
number
trp
residu
requir
optim
activ
toxic
observ
host
cell
compound
concentr
interestingli
dendrim
ia
ec
contain
peripher
trp
residu
dival
spacer
arm
equal
activ
prototyp
ec
peripher
trp
residu
trival
spacer
arm
result
suggest
although
activ
seem
mainli
relat
number
peripher
trp
residu
featur
molecul
specif
orient
trp
residu
andor
lower
congest
peripher
amino
acid
import
activ
determin
stage
hiv
replic
cycl
compound
act
timeofdrugaddit
studi
perform
potent
iia
differ
wellcharacter
anti
hiv
drug
use
refer
drug
inhibitor
entryfus
process
adsorpt
inhibitor
use
azt
use
revers
transcriptas
inhibitor
shown
fig
full
protect
activ
achiev
iia
ad
earli
cell
almost
within
h
hiv
ad
howev
iia
lost
activ
ad
hiv
experi
clearli
show
iia
need
present
cell
cultur
start
viru
infect
bindingadsorpt
period
thu
conclud
compound
iia
like
prototyp
interfer
earli
event
replic
cycl
hiv
like
inhibit
entri
hiv
suscept
human
cell
next
potenti
bind
iia
virusencod
envelop
glycoprotein
use
surfac
plasmon
reson
spr
technolog
investig
prma
use
posit
control
prma
compound
iia
clearli
show
high
bind
signal
confirm
hiv
interact
next
detail
sprdirect
affin
determin
use
concentr
iia
rang
appar
k
bind
iia
fig
tabl
sub
micromolar
rang
k
time
pronounc
found
posit
control
prma
k
member
dendrim
famili
trival
branch
arm
k
riverobuceta
new
compound
iad
iiad
also
evalu
determin
select
antivir
activ
ec
brcr
laboratoryadapt
strain
viruscellbas
assay
rhabdomyosarcoma
rd
cell
yamayoshi
toxic
cc
also
assess
similar
way
compoundtr
uninfect
cell
tabl
summar
result
evalu
antivir
data
prototyp
capsid
binder
pirodavir
includ
refer
andri
dendrim
dival
branch
arm
iad
inact
ib
ic
much
less
activ
ia
id
prototyp
dendrim
tetraval
branch
arm
iiad
show
similar
activ
ec
prototyp
ec
among
iia
ec
iid
ec
show
highest
activ
case
contrast
hiv
wide
differ
activ
observ
ia
ec
branch
dival
arm
peripher
trp
residu
prototyp
ec
trival
branch
arm
peripher
trp
residu
suggest
greater
degre
multival
might
import
activ
addit
activ
compound
iia
iid
evalu
viruscellbas
assay
repres
clinic
isol
interestingli
previous
report
trp
prototyp
ec
nm
riverobuceta
select
dendrim
iia
iid
extrem
potent
inhibitor
clinic
isol
activ
nanomolar
rang
ec
iia
nm
ec
iid
nm
support
inform
tabl
differ
brcr
laboratori
clinic
strain
observ
cell
treat
classic
capsid
binder
like
pirodavir
data
shown
find
suggest
trp
dendrim
act
novel
mechan
action
differ
classic
capsid
binder
tijsma
determin
novel
trp
dendrim
iiad
whose
structur
close
relat
would
retain
mechan
action
cross
resist
studi
perform
potent
compound
iia
compound
evalu
inhibitori
activ
variant
re
confer
resist
prototyp
sun
tabl
support
inform
fig
interestingli
iia
retain
antivir
activ
ec
mutant
viru
strain
although
activ
least
lower
wildtyp
viru
contrast
rupintrivir
proteas
inhibitor
retain
full
antivir
activ
mutant
viru
strain
overal
data
suggest
iia
similar
mechan
antivir
activ
resist
parent
prototyp
thu
interact
fivefold
axi
capsid
howev
exclud
may
show
addit
interact
amino
acid
fivefold
axi
thu
account
residu
activ
mutant
virus
synthes
compound
iad
iiad
also
assay
varieti
rna
dna
virus
interestingli
dendrim
tetraval
branch
arm
iiad
show
signific
activ
herp
simplex
viru
type
human
corona
viru
e
respiratori
syncyti
viru
support
inform
tabl
fig
contrast
prototyp
reveal
inhibitori
activ
virus
data
shown
riverobuceta
compound
iib
ec
contain
flexibl
central
scaffold
show
less
antivir
activ
compound
iia
iic
iid
ec
rigid
central
scaffold
contrast
iib
ec
activ
e
iia
iic
iid
ec
show
structur
requir
activ
differ
virus
particularli
import
activ
show
compound
ii
c
herp
simplex
viru
genit
herp
viru
consid
import
risk
factor
hiv
infect
barnava
desai
munawwar
interestingli
immunofluoresc
experi
reveal
potent
iia
support
inform
tabl
inhibit
bind
monoclon
antibodi
mab
direct
envelop
support
inform
tabl
support
interact
iia
viral
surfac
final
broad
antimicrobi
screen
carri
compound
ia
iia
pathogen
test
includ
gram
posit
neg
bacteria
yeast
candida
albican
none
test
compound
show
inhibitori
activ
pathogen
subtox
concentr
summari
new
seri
trp
dendrim
contain
dival
tetraval
branch
arm
instead
trival
one
present
prototyp
synthes
use
converg
diverg
approach
find
demonstr
compound
tetraval
branch
arm
iiad
show
similar
inhibitori
activ
hiv
laboratori
strain
prototyp
interestingli
previous
report
extrem
potent
inhibitor
clinic
isol
lownanomolarhighpicomolar
potenc
notabl
compound
also
endow
signific
inhibitori
activ
e
respiratori
syncyti
viru
first
member
trp
dendrim
famili
show
activ
virus
experiment
work
carri
determin
mode
action
potent
iia
demonstr
interact
viral
envelop
hiv
probabl
prevent
viru
attach
host
cell
mayb
bind
site
respect
viral
surfac
figur
show
one
three
replic
experi
latter
use
posit
control
surfac
color
curv
repres
realtim
bind
respons
black
curv
indic
calcul
langmuir
model
fit
concentr
iia
rang
prma
analyt
dilut
use
twofold
dilut
step
analyt
abil
bind
confirm
averag
standard
deviat
kinet
paramet
obtain
three
replic
spr
experi
measur
bind
respons
iiaprma
adequ
residu
establish
electrostat
hydrogen
bond
van
der
waal
interact
neg
charg
indol
sidechain
trp
residu
find
support
interest
new
famili
trp
dendrim
qualifi
attract
lead
compound
develop
new
viral
entri
inhibitor
broad
antivir
spectrum
